Senescent-Like Myofibers Contribute to Anti-Regenerative Cytokine Signaling in Duchenne Muscular Dystrophy

Masanari Ikeda1, Yukie Tanaka1, Hidetoshi Sugihara1

  • 1Laboratory of Veterinary Physiology, Graduate School of Agricultural and Life Sciences, The University of Tokyo, Tokyo, Japan.

Insights

In Duchenne muscular dystrophy (DMD), p16 protein drives muscle degeneration by increasing inflammatory cytokines. Ablating p16 improves muscle regeneration in DMD rats, revealing a new therapeutic target.

Area of Science:

  • Molecular Biology
  • Genetics
  • Regenerative Medicine

Background:

  • Duchenne muscular dystrophy (DMD) is a progressive genetic muscle-wasting disease.
  • Cellular senescence, involving p16 expression, is implicated in DMD pathophysiology.
  • The precise mechanism of p16's role in DMD exacerbation and muscle regeneration is not fully understood.

Purpose of the Study:

  • To elucidate the mechanism by which p16 exacerbates Duchenne muscular dystrophy.
  • To investigate the role of p16 in modulating the muscle microenvironment and regeneration capacity in DMD.

Main Methods:

  • RNA sequencing (RNA-seq) to analyze gene expression in DMD rat skeletal muscle.
  • Assessment of systemic cytokine profiles in DMD and control rats.
  • Transplantation of extensor digitorum longus muscles to evaluate regeneration in altered humoral environments.
  • Analysis of p16 and cytokine expression in isolated myofibers.

Main Results:

  • RNA-seq identified p16-dependent upregulation of cytokine genes in DMD rat skeletal muscles.
  • DMD rats exhibited altered systemic blood cytokine profiles compared to controls.
  • Muscle regeneration was suppressed in DMD rats but significantly improved following p16 ablation.
  • p16 expression was detected in DMD rat myofibers, which also showed p16-dependent cytokine expression.

Conclusions:

  • Cytokines secreted by p16-expressing, senescent-like myofibers create an anti-regenerative niche in DMD.
  • This study uncovers a novel mechanism contributing to DMD progression.
  • Targeting p16-mediated cytokine signaling presents a potential therapeutic strategy for DMD.